AmpliTech Group, Inc. (AMPG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 16, 2024, discloses a material definitive agreement entered into by AmpliTech Group, Inc. The filing details a registered direct offering of common stock and related agreements with institutional investors and a placement agent.
Key Financial Metrics and Transaction Details
- Offering Size: 1,516,680 shares of common stock.
- Price Per Share: $2.10.
- Gross Proceeds: Approximately $3,185,028 (before fees and expenses).
- Placement Agent Fee: 7.0% of aggregate gross proceeds.
- Expense Reimbursement: Up to $30,000 for accountable expenses, including legal fees.
- Closing Date: Expected December 18, 2024.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with two institutional investors. Concurrently, a Placement Agency Agreement was signed with Maxim Group LLC. Additionally, a Lock-Up Agreement was executed, restricting directors and executive officers from selling or transferring common stock or convertible securities for 45 days following the Closing Date. Investors from prior agreements dated November 24, 2024, and December 11, 2024, waived their 45-day prohibition on issuance to facilitate this transaction.
Guidance, Outlook, and Restrictions
The filing does not provide specific financial guidance or management commentary regarding future operational performance. However, the Company has agreed to a 45-day standstill period following the Closing Date, during which it will not issue, agree to issue, or announce the issuance of common stock or convertible securities, subject to certain exceptions. This restriction also applies to Variable Rate Transactions.
Key Facts for Investor Verification
- Verify the actual closing of the transaction on or around December 18, 2024.
- Confirm the net proceeds after deducting the 7.0% placement fee and up to $30,000 in reimbursable expenses.
- Monitor the 45-day lock-up period for directors and officers to assess potential market supply constraints.
- Review the Prospectus Supplement (filed December 16, 2024) for detailed risk factors and use of proceeds.
- Note that the filing text does not provide current revenue, profit, cash flow, or debt metrics; these are not the subject of this specific 8-K.